Takehiko Mima1, Herbert P Schweizer, Ze-Qi Xu. 1. Department of Microbiology, Immunology and Pathology, Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Colorado State University, Fort Collins, CO 80523-2025, USA.
Abstract
OBJECTIVES: most Burkholderia pseudomallei strains are intrinsically resistant to macrolides, mainly due to AmrAB-OprA- and/or BpeAB-OprB-mediated efflux. We assessed the in vitro anti-B. pseudomallei efficacy of cethromycin, a novel ketolide with broad-spectrum activity against Gram-negative and Gram-positive pathogens. METHODS: the 2-fold broth microdilution technique was used to assess the in vitro cethromycin susceptibility of a prototype strain, efflux mutants, and a panel of 60 clinical and environmental strains. Time-kill curves were used to assess the mode of action. Spontaneous resistant mutants were isolated and AmrAB-OprA efflux pump expression assessed by quantitative real-time PCR. Deletion and complementation analyses were performed to demonstrate AmrAB-OprA efflux pump mutant involvement in high-level cethromycin resistance. RESULTS: in contrast to macrolides, cethromycin was a weak substrate of AmrAB-OprA and BpeAB-OprB. Cethromycin was bactericidal at high concentrations and bacteriostatic at MIC levels. The ketolide showed efficacy against clinical and environmental strains of B. pseudomallei, with MIC values ranging from 4 to 64 mg/L. Environmental isolates were consistently more susceptible than clinical isolates. High-level cethromycin resistance (MIC 128 mg/L) was due to constitutive AmrAB-OprA efflux pump overexpression, but other mechanisms also seem to contribute. CONCLUSIONS: in contrast to macrolides, which are readily effluxed, cethromycin is weakly extruded in wild-type strains and thus demonstrates significant in vitro anti-B. pseudomallei activity against diverse strains. Acquired high-level cethromycin resistance is caused by constitutive AmrAB-OprA efflux pump overexpression and other, probably non-efflux, mechanisms may also contribute to lower-level acquired resistance.
OBJECTIVES: most Burkholderia pseudomallei strains are intrinsically resistant to macrolides, mainly due to AmrAB-OprA- and/or BpeAB-OprB-mediated efflux. We assessed the in vitro anti-B. pseudomallei efficacy of cethromycin, a novel ketolide with broad-spectrum activity against Gram-negative and Gram-positive pathogens. METHODS: the 2-fold broth microdilution technique was used to assess the in vitro cethromycin susceptibility of a prototype strain, efflux mutants, and a panel of 60 clinical and environmental strains. Time-kill curves were used to assess the mode of action. Spontaneous resistant mutants were isolated and AmrAB-OprA efflux pump expression assessed by quantitative real-time PCR. Deletion and complementation analyses were performed to demonstrate AmrAB-OprA efflux pump mutant involvement in high-level cethromycin resistance. RESULTS: in contrast to macrolides, cethromycin was a weak substrate of AmrAB-OprA and BpeAB-OprB. Cethromycin was bactericidal at high concentrations and bacteriostatic at MIC levels. The ketolide showed efficacy against clinical and environmental strains of B. pseudomallei, with MIC values ranging from 4 to 64 mg/L. Environmental isolates were consistently more susceptible than clinical isolates. High-level cethromycin resistance (MIC 128 mg/L) was due to constitutive AmrAB-OprA efflux pump overexpression, but other mechanisms also seem to contribute. CONCLUSIONS: in contrast to macrolides, which are readily effluxed, cethromycin is weakly extruded in wild-type strains and thus demonstrates significant in vitro anti-B. pseudomallei activity against diverse strains. Acquired high-level cethromycin resistance is caused by constitutive AmrAB-OprA efflux pump overexpression and other, probably non-efflux, mechanisms may also contribute to lower-level acquired resistance.
Authors: Sharon J Peacock; Herbert P Schweizer; David A B Dance; Theresa L Smith; Jay E Gee; Vanaporn Wuthiekanun; David DeShazer; Ivo Steinmetz; Patrick Tan; Bart J Currie Journal: Emerg Infect Dis Date: 2008-07 Impact factor: 6.883
Authors: W Joost Wiersinga; Tom van der Poll; Nicholas J White; Nicholas P Day; Sharon J Peacock Journal: Nat Rev Microbiol Date: 2006-04 Impact factor: 60.633
Authors: Lily A Trunck; Katie L Propst; Vanaporn Wuthiekanun; Apichai Tuanyok; Stephen M Beckstrom-Sternberg; James S Beckstrom-Sternberg; Sharon J Peacock; Paul Keim; Steven W Dow; Herbert P Schweizer Journal: PLoS Negl Trop Dis Date: 2009-09-22
Authors: Jason A Rosenzweig; Sheri M Brackman; Michelle L Kirtley; Jian Sha; Tatiana E Erova; Linsey A Yeager; Johnny W Peterson; Ze-Qi Xu; Ashok K Chopra Journal: Antimicrob Agents Chemother Date: 2011-08-22 Impact factor: 5.191
Authors: Julia V Bugrysheva; David Sue; Jay E Gee; Mindy G Elrod; Alex R Hoffmaster; Linnell B Randall; Sunisa Chirakul; Apichai Tuanyok; Herbert P Schweizer; Linda M Weigel Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Nawarat Somprasong; Jinhee Yi; Carina M Hall; Jessica R Webb; Jason W Sahl; David M Wagner; Paul Keim; Bart J Currie; Herbert P Schweizer Journal: Antimicrob Agents Chemother Date: 2021-08-17 Impact factor: 5.191
Authors: Fabrice V Biot; Eric Valade; Eric Garnotel; Jacqueline Chevalier; Claude Villard; François M Thibault; Dominique R Vidal; Jean-Marie Pagès Journal: PLoS One Date: 2011-02-09 Impact factor: 3.240
Authors: Fabrice Vincent Biot; Mélanie Monique Lopez; Thomas Poyot; Fabienne Neulat-Ripoll; Sabrina Lignon; Arnaud Caclard; François Michel Thibault; Andre Peinnequin; Jean-Marie Pagès; Eric Valade Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240